1-3 of 3
Stanley C. Gill, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Mark Litzow, MD, Maria R. Baer, MD, David F. Claxton, MD, Harry P. Erba, MD PhD, Stanley C. Gill, PhD, Stuart L. Goldberg, MD, Joseph G. Jurcic, MD, Richard A. Larson, MD, Charles Liu, PhD, Ellen K. Ritchie, MD, Gary J. Schiller, MD, Alexander I. Spira, MD PhD, Stephen A. Strickland, Raoul Tibes, MD PhD, Celalettin Ustun, MD, Eunice S. Wang, MD, Robert K. Stuart, MD, Christoph Röllig, MD, Andreas Neubauer, Giovanni Martinelli, Erkut Bahceci, MD, Mark J. Levis, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1069.
https://doi.org/10.1182/blood.V128.22.1069.1069
Published: 2016
Journal Articles

Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study

Jessica K. Altman, MD, Alexander E. Perl, MD, Jorge E. Cortes, MD, Mark J. Levis, MD PhD, Catherine C. Smith, MD, Mark R Litzow, MD, Maria R. Baer, David F. Claxton, MD, Harry P. Erba, MD PhD, Stanley C. Gill, PhD, Stuart L. Goldberg, Joseph G. Jurcic, MD, Richard A. Larson, MD, Charles Lui, PhD, Ellen K Ritchie, MD, Briana Sargent, BS, Gary J Schiller, MD, Alexander I. Spira, MD PhD, Stephen A. Strickland, MD, Raoul Tibes, MD PhD, Celalettin Ustun, MD, Eunice S. Wang, MD, Robert K. Stuart, MD, Claudia D. Baldus, MD PhD, Christoph Rollig, Andreas Neubauer, MD, Giovanni Martinelli, Erkut Bahceci, MD
Journal: Blood
Blood (2015) 126 (23): 321.
https://doi.org/10.1182/blood.V126.23.321.321
Published: 2015
Journal Articles

Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study

Catherine C. Smith, MD, Mark J. Levis, MD PhD, Mark R Litzow, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Stanley C. Gill, PhD, Takeshi Kadokura, PhD, Geoffrey J. Yuen, Pharm.D., Ogert Fisniku, MS, Charles Liu, PhD, Itsuro Nagase, PhDDVM, Briana Sargent, BS, Noreen Welter, RN, BSN, Erkut Bahceci, MD
Journal: Blood
Blood (2015) 126 (23): 4836.
https://doi.org/10.1182/blood.V126.23.4836.4836
Published: 2015